SRZN

Surrozen, Inc. (SRZN) | Rumor.io

Surrozen

SRZN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,965

Bullish sentiment (50-day avg)52%

Price to earnings ratio-0.92

Market capitalization348.4M

Earnings per share-40.1

Dividend yield (TTM)—

Revenue (annual)3.5M

Net income (annual)-242M

Social

What share of all stock conversation is about SRZN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 25

H.C. Wainwright raises Surrozen price target on Wnt pathway validation.
Surrozen's stock is fading off its highs, with volume drying up fast, despite a 2.32M float and 1.44M shares short.
Surrozen's short position is being accumulated, with a plan to buy back shares after the offering, when volume increases.

Generated by AI

Sentiment

Of the messages about SRZN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +25	51.59% -48.41	52.34%	75.93% -11.57
Bearish	50% -25	48.41% +48.41	47.66%	24.07% +11.57

Bullish· Sep 24

$SRZN has a 100% buy rating with a price target of $44+, according to a recent analysis.
Institutional ownership of $SRZN is at 103.86%, with institutions and insiders owning the majority of the float.
$SRZN has a strong pipeline with millions being spent on preclinical studies, and analysts expect significant growth in the future.

Bearish· Sep 24

Surrozen has less than $100 million in cash reserves, and will likely need to issue new shares soon to continue funding its trials.
The company's lead drug, SZN-8141, has never been tested in humans, and the first human data is not expected until H2 2027, making it a significant risk for investors.
The company's cash burn rate is high, and it has significant potential for dilution through its ATM, PIPE, and warrants, which could further depress the stock price.

Generated by AI

Topics

Of the messages about SRZN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	30.88%	31.88%	69.97%
Analysts	—	19.12%	18.84%	17.72%
Macro	—	33.82%	33.33%	6.91%
Technical Analysis	—	16.18%	15.94%	4.8%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.6%

Feb 13

Shares of SRZN Surrozen have seen a rapid price rise on high relative volume, currently trading at $1.27.
The stock has increased 11% since the previous day's close.
SRZN is considered a low float stock.

Generated by AI

Community

Of the messages about SRZN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	12.42%	12.13%	36.57%
Newcomers	100%	87.58%	87.87%	63.43%

Regulars· Sep 24

$SRZN is currently trading at 1.60, with a strong uptrend and a potential trend line crack that could lead to shorting and selling.
The stock's float is 10 million, and its strong uptrend has resulted in a 62% gain for mid-cap investors.
The patent battle between Merck and Surrozen, Inc. may be nearing a settlement, with Merck potentially deciding to license or buy the company, which could attract interest from other companies like Roche, Regeneron, and BI.

Newcomers· Sep 25

$SRZN stock surged +108% on an IND deal, with a large short interest of 62.19% and a relatively low float of 2.32M shares.
H.C. Wainwright raised Surrozen's price target, which some users see as a sign of the company's potential, but others are skeptical about the timing and the fact that the analyst may be participating in the upcoming offering.
The stock's price is expected to be affected by the upcoming offering, with some users anticipating a short squeeze and others predicting a crash, while others are looking to accumulate the stock at a lower price.

Generated by AI

Gainers Apimeds Pharmaceuticals (AMEX:APUS) shares increased by 162.4% to $6.01 during Thursday's regular session. The market value of their outstanding shares is at $3.4 million. Surrozen (NASDAQ:SRZN) stock

5d agobenzinga.com

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy - Surrozen (NASDAQ:SRZN)

Surrozen submitted an IND application to the FDA for SZN-8141 to treat diabetic macular edema, with trial data expected in late 2027.

5d agobenzinga.com

Also Discussed

Investors talking about SRZN also mention

#	Name	Attention
1	Cyclerion Therapeutics IncCYCN	0%new
2	EFTR - eFFECTOR Therapeutics, Inc.	——
3	ACHL - Achilles Therapeutics plc	——
4	KRON - Kronos Bio, Inc.	——
5	Addex Therapeutics LtdADXN	0%0
6	Expion360 Inc.XPON	0%0
7	Direct Digital Holdings, Inc. Class A Common StockDRCT	0%0
8	Cullinan Therapeutics Inc.CGEM	0%new
9	VRNA - Verona Pharma plc	——
10	Cosmos Health Inc.COSM	0.02%+0.01

Surrozen, Inc.

Healthcare
Biotechnology

Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration. The company’s current programs are centered on ophthalmology, with candidates aimed at retinal diseases, diabetic macular edema, wet age-related macular degeneration, uveitic macular edema, Fuchs’ endothelial corneal dystrophy, and geographic atrophy. Surrozen also works on tissue-specific biologics designed to engage the body’s natural repair mechanisms in other disease areas, including the intestine, liver, lung, kidney, skin, pancreas, and central nervous system. Based in South San Francisco, California, Surrozen’s role in the market is that of a clinical-stage drug developer pursuing precision biologics for serious conditions with high unmet medical need.

Website

Location

171 Oyster Point Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about SRZN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 25

H.C. Wainwright raises Surrozen price target on Wnt pathway validation.
Surrozen's stock is fading off its highs, with volume drying up fast, despite a 2.32M float and 1.44M shares short.
Surrozen's short position is being accumulated, with a plan to buy back shares after the offering, when volume increases.

Generated by AI

Sentiment

Of the messages about SRZN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% +25	51.59% -48.41	52.34%	75.93% -11.57
Bearish	50% -25	48.41% +48.41	47.66%	24.07% +11.57

Bullish· Sep 24

$SRZN has a 100% buy rating with a price target of $44+, according to a recent analysis.
Institutional ownership of $SRZN is at 103.86%, with institutions and insiders owning the majority of the float.
$SRZN has a strong pipeline with millions being spent on preclinical studies, and analysts expect significant growth in the future.

Bearish· Sep 24

Surrozen has less than $100 million in cash reserves, and will likely need to issue new shares soon to continue funding its trials.
The company's lead drug, SZN-8141, has never been tested in humans, and the first human data is not expected until H2 2027, making it a significant risk for investors.
The company's cash burn rate is high, and it has significant potential for dilution through its ATM, PIPE, and warrants, which could further depress the stock price.

Generated by AI

Topics

Of the messages about SRZN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	30.88%	31.88%	69.97%
Analysts	—	19.12%	18.84%	17.72%
Macro	—	33.82%	33.33%	6.91%
Technical Analysis	—	16.18%	15.94%	4.8%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.6%

Feb 13

Shares of SRZN Surrozen have seen a rapid price rise on high relative volume, currently trading at $1.27.
The stock has increased 11% since the previous day's close.
SRZN is considered a low float stock.

Generated by AI

Community

Of the messages about SRZN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	12.42%	12.13%	36.57%
Newcomers	100%	87.58%	87.87%	63.43%

Regulars· Sep 24

$SRZN is currently trading at 1.60, with a strong uptrend and a potential trend line crack that could lead to shorting and selling.
The stock's float is 10 million, and its strong uptrend has resulted in a 62% gain for mid-cap investors.
The patent battle between Merck and Surrozen, Inc. may be nearing a settlement, with Merck potentially deciding to license or buy the company, which could attract interest from other companies like Roche, Regeneron, and BI.

Newcomers· Sep 25

$SRZN stock surged +108% on an IND deal, with a large short interest of 62.19% and a relatively low float of 2.32M shares.
H.C. Wainwright raised Surrozen's price target, which some users see as a sign of the company's potential, but others are skeptical about the timing and the fact that the analyst may be participating in the upcoming offering.
The stock's price is expected to be affected by the upcoming offering, with some users anticipating a short squeeze and others predicting a crash, while others are looking to accumulate the stock at a lower price.

Generated by AI

Surrozen

Social

Sep 25

Sentiment

Bullish· Sep 24

Bearish· Sep 24

Topics

Feb 13

Community

Regulars· Sep 24

Newcomers· Sep 25

News

H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation

12 Health Care Stocks Moving In Thursday's Intraday Session - Apimeds Pharmaceuticals (AMEX:APUS), Surroz

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy - Surrozen (NASDAQ:SRZN)

Surrozen at Morgan Stanley conference: eyeing dual-action edge

Surrozen at Cantor healthcare conference: eye drug strategy takes shape

Guggenheim Names Top Biotechnology Stock Pick

Also Discussed

Surrozen, Inc.

Company Information

Location

News

H.C. Wainwright raises Surrozen stock price target on Wnt pathway validation

12 Health Care Stocks Moving In Thursday's Intraday Session - Apimeds Pharmaceuticals (AMEX:APUS), Surroz

Surrozen Gains Momentum as FDA Submission Opens Path for Lead Therapy - Surrozen (NASDAQ:SRZN)

Surrozen at Morgan Stanley conference: eyeing dual-action edge

Surrozen at Cantor healthcare conference: eye drug strategy takes shape

Guggenheim Names Top Biotechnology Stock Pick

Also Discussed

Social

Sep 25

Sentiment

Bullish· Sep 24

Bearish· Sep 24

Topics

Feb 13

Community

Regulars· Sep 24

Newcomers· Sep 25